●

トップページ

 ●

ご挨拶

 ●

教室員

 ●

研究内容

 ●

研究費
●

研究成果

 ●

使用可能機器

 ●

学生の方へ

 ●

アクセス

 ●

サイトマップ

英語論文（2010年以降）


　Corresponding authorは名前の後ろに「*」
  1. Naoi Y, Morinaga T, Nagasaki J, Ariyasu R, Ueda Y, Yamashita K, Zhou W, Kawashima S, Kawase K, Honobe-Tabuchi A, Ohnuma T, Kawamura T, Umeda Y, Kawahara Y, Nakamura Y, Kiniwa Y, Yamasaki O, Fukushima S, Kawazu M, Suzuki Y, Nishikawa H, Hanazawa T, Ando M, Inozume T, Togashi Y*.
    CD106 in tumor-specific exhausted CD8+ T cells mediates immunosuppression by inhibiting TCR signaling.
    Cancer Res, in press, 2024.
    DOI: 10.1158/0008-5472.CAN-23-0453 PMID: 38635899

  2. Zhou W, Kawashima S, Ishino T, Kawase K, Ueda Y, Yamashita K, Watanabe T, Kawazu M, Dansako H, Suzuki Y, Nishikawa H, Inozume T, Nagasaki J*, Togashi Y*.
    Stem-like Progenitor and Terminally Differentiated TFH-like CD4+ T cell Exhaustion in the Tumor Microenvironment
    Cell Rep, 43(2):113797, 2024.
    DOI: 10.1016/j.celrep.2024.113797 PMID: 38363680

  3. Okumura K, Morinaga T, Saito M, Tokunaga Y, Otoyama K, Tanaka S, Isogai E, Kawazu M, Togashi Y, Araki K, Wakabayashi Y*.
    Deletion of Pak1 in CD11c positive cells confers resistance to mouse skin carcinogenesis.
    J Invest Dermatol, in press, 2024.
    DOI: 10.1016/j.jid.2024.01.021 PMID: 38325578

  4. Dansako H*, Ikeda M, Ariumi Y, Togashi Y, Kato N.
    Hepatitis C virus NS5B triggers an MDA5-mediated innate immune response by producing dsRNA without the replication of viral genomes.
    FEBS J, 291(6):1119-1130, 2024
    DOI: 10.1111/febs.16980 PMID: 37863517

  5. Kemmotsu N, Ninomiya K, Kunimasa K, Ishino T, Nagasaki J, Otani Y, Michiue H, Ichihara E, Ohashi K, Inoue T, Tamiya M, Sakai K, Ueda Y, Dansako H, Nishio K, Kiura K, Date I, Togashi Y*.
    Low frequency of intracranial progression in advanced NSCLC patients treated with cancer immunotherapies.
    Int J Cancer, 154(1):169-179, 2024.
    DOI:10.1002/ijc.34700 PMID:37611176

  6. Immunological Significance of CD80/CD86 or Major Histocompatibility Complex-II Expression in Thymic Epithelial Tumors.
    Ikeda H, Nagasaki J, Shimizu D, Katsuya Y, Horinouchi H, Hosomi Y, Tanji E, Iwata T, Itami M, Kawazu M, Ohe Y, Suzuki T, Togashi Y*.
    JTO Clin Res Rep, 4(10):100573, 2023.
    DOI: 10.1016/j.jtocrr.2023.100573 PMID: 37799325

  7. Kemmotsu N, Zhu L, Nagasaki J, Otani Y, Ueda Y, Dansako H, Fang Y, Date I, Togashi Y*.
    Combination therapy with hydrogen peroxide and irradiation promotes an abscopal effect in mouse models.
    Cancer Sci, 114(10):3848-3856, 2023.
    DOI:10.1111/cas.15911 PMID:37485636

  8. Watanabe T, Ishino T, Ueda Y, Nagasaki J, Sadahira T, Dansako H, Araki Motoo, Togashi Y*.
    Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity.
    Cancer Sci, 114(5):1859-1870, 2023.
    DOI:10.1111/cas.15756 PMID:36762794

  9. Kawase K, Kawashima S, Nagasaki J, Inozume T, Tanji E, Kawazu M, Hanazawa T, Togashi Y*.
    High Expression of MHC Class I Overcomes Cancer Immunotherapy Resistance Due to IFNγ Signaling Pathway Defects.
    Cancer Immunol Res, 11(7):895-908, 2023
    DOI:10.1158/2326-6066.CIR-22-0815 PMID:37062030

  10. Ishino T, Kawashima S, Tanji E, Ueno T, Ueda Y, Ogasawara S, Sato K, Mano H, Ishihara S, Kato N, Kawazu M*, Togashi Y*.
    Somatic mutations can induce a noninflamed tumour microenvironment via their original gene functions, despite deriving neoantigens
    Br J Cancer ,128(6):1166-1175, 2023.
    DOI:10.1038/s41416-023-02165-6 PMID:36732592

  11. Shingaki S, Koya J, Yuasa M, Saito Y, Tabata M, McClure MB, Ogawa S, Katayama K, Togashi Y, Imoto S, Kogure Y, Kataoka K*.
    Tumor-promoting function and regulatory landscape of PD-L2 in B-cell lymphoma.
    Leukemia, 37(2):492-496, 2023.
    DOI:10.1038/s41375-022-01772-1 PMID:36522456

  12. Kawashima S, Togashi Y*.
    Resistance to immune checkpoint inhibitors and the tumor microenvironment.
    Exp Dermatol. 32(3):240-249, 2023.
    DOI:10.1111/exd.14716 PMID:36437644

  13. Nagasaki J, Ishino T, Togashi Y*.
    Mechanisms of resistance to immune checkpoint inhibitors.
    Cancer Sci, 113:3303-3312, 2022.
    DOI:10.1111/cas.15497 PMID:35848888

  14. Nagasaki J, Togashi Y*.
    A variety of 'exhausted' T cells in the tumor microenvironment.
    Int Immunol, 34:563-570, 2022.
    DOI:10.1093/intimm/dxac013 PMID:35460561

  15. Ymamoto H, Togashi Y*.
    Programmed Death-Ligand 1 Rich Premetastatic Niche in Adjuvant Chemotherapy.
    J Thorac Oncol, 17(1):10-12, 2022.
    DOI 10.1016/j.jtho.2021.10.019 : PMID:34930604

  16. Ikeda H, Togashi Y*.
    Aging, cancer, and antitumor immunity.
    Int J Clin Oncol, 27:316-322.
    DOI:10.1007/s10147-021-01913-z PMID:33783658

  17. Bando H, Tsukada Y, Inamori K, Togashi Y, Koyama S, Kotani D, Fukuoka S, Yuki S, Komatsu Y, Homma S, Taketomi A, Uemura M, Kato T, Fukui M, Wakabayashi M, Nakamura N, Kojima M, Kawachi H, Kirsch R, Yoshida T, Suzuki Y, Sato A, Nishikawa H, Ito M, Yoshino T*.
    Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer.
    Clin Cancer Res, in press, 2022.
    DOI:10.1158/1078-0432.CCR-21-3213 PMID: 35063964

  18. Kumagai S, Koyama S*, Itahashi K, Tanegashima T, Lin YT, Togashi Y, Kamada T, Irie T, Okumura G, Kono H, Ito D, Fujii R, Watanabe S, Sai A, Fukuoka S, Sugiyama E, Watanabe G, Owari T, Nishinakamura H, Sugiyama D, Maeda Y, Kawazoe A, Yukami H, Chida K, Ohara Y, Yoshida T, Shinno Y, Takeyasu Y, Shirasawa M, Nakama K, Aokage K, Suzuki J, Ishii G, Kuwata T, Sakamoto N, Kawazu M, Ueno T, Mori T, Yamazaki N, Tsuboi M, Yatabe Y, Kinoshita T, Doi T, Shitara K, Mano H, Nishikawa H*.
    Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments.
    Cancer Cell, 40(2):201-218, 2022.
    DOI: 10.1016/j.ccell.2022.01.001 PMID:35090594

  19. Nagasaki J, Inozume T, Sax N, Ariyasu R, Ishikawa M, Yamashita K, Kawazu M, Ueno T, Irie T, Tanji E, Morinaga T, Honobe A, Ohkura T, Yoshino M, Iwata T, Kawase K, Sasaki K, Hanazawa t, Kochin V, Kawamura T, Matsue H, Hino M, Mano, H, Suzuki Y, Nishikawa H, Togashi Y*.
    PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes.
    Cell Rep, 38(5):110331, 2022.
    DOI:10.1016/j.celrep.2022.110331 PMID:35108529

  20. Kawazu M*, Ueno T, Saeki K, Sax N, Togashi Y, Kaneseki T, Chida K, Kishigami F, Sato K, Kojima S, Otsuka M, Kawazoe A, Nishinakamura H, Maeda Y, Yamamoto Y, Yamashita K, Inoue S, Tanegashima T, Matsubara D, Tane K, Tanaka Y, Iinuma H, Hashiguchi Y, Hazama S, Khor SS, Tokunaga K, Tsuboi M, Niki T, Eto M, Shitara K, Torigoe T, Ishihara S, Aburatani H, Haeno H, Nishikawa H, Mano H.
    HLA Class I analysis provides insight into the genetic and epigenetic background of immune evasion in colorectal cancer with high microsatellite instability.
    Gastroenteology, 162(3):799-812, 2022.
    DOI:10.1053/j.gastro.2021.10.010 PMID:34687740

  21. Namba S, Ueno T, Kojima S, Kobayashi K, Kawase K, Tanaka Y, Inoue S, Kishigami F, Kawashima S, Maeda N, Ogawa T, Hazama S, Togashi Y, Ando M, Shiraishi Y, Mano H, Kawazu M*.
    Transcript-targeted analysis reveals isoform alterations and double-hop fusions in breast cancer.
    Commun Biol, 4(1):1320, 2021.
    DOI:10.1038/s42003-021-02833-4 PMID:34811492

  22. Kawashima S, Inozume T, Kawazu M, Ueno T, Nagasaki J, Tanji E, Honobe A, Ohnuma T, Kawamura T, Umeda Y, Nakamura Y, Kawasaki T, Kiniwa Y, Yamasaki O, Fukushima S, Ikehara Y, Mano H, Suzuki Y, Nishikawa H, Matsue H, Togashi Y*.
    TIGIT/CD155 axis mediates resistance to immunotherapy in melanoma patients with the inflamed tumor microenvironment.
    J Immunother Cancer, 9(11):e003134, 2021.
    DOI: 10.1136/jitc-2021-003134 PMID:34795004

  23. Takeuchi Y, Tanegashima T, Sato E, Irie T, Sai A, Itahashi K, Kumagai S, Tada Y, Togashi Y, Koyama S, Akbay EA, Karasaki T, Kataoka K, Funaki S, Shintani Y, Nagatomo I, Kida H, Ishii G, Miyoshi T, Aokage K, Kakimi K, Ogawa S, Okumura M, Eto M, Kumanogoh A, Tsuboi M, Nishikawa H.
    Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape.
    Sci Immunol, 6(65):eabc6424, 2021.
    DOI10.1126/sciimmunol.abc6424 : PMID:34767457

  24. Koya J, Saito Y, Kameda T, Kogure Y, Yuasa M, Nagasaki J, McClure MB, Shingaki S, Tabata M, Tahira Y, Akizuki K, Kamiunten A, Sekine M, Shide K, Kubuki Y, Hidaka T, Kitanaka A, Nakano N, Utsunomiya A, Togashi Y, Ogawa S, Shimoda K, Kataoka K.
    Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1.
    Blood Cancer Discov, 2(5):450-467, 2021.
    DOI:10.1158/2643-3230.BCD-21-0044 PMID:34661162

  25. Dansako H*, Ueda Y, Satoh S, Kato N.
    Extracellular vesicles activate ATM-Chk2 signaling pathway through the intercellular transfer of mitochondrial DNA in HBV-infected human hepatocytes.
    FASEB J, 35(6):e21680, 2021.
    DOI:10.1096/fj.202002678R PMID:34042225

  26. Inamori K, Togashi Y*, Fukuoka S, Akagi K, Ogasawara K, irie T, Motooka D, Kobayashi Y, Sugiyama D, Kojima M, Shiiya N, Nakamura S, Murayama S, Suzuki Y, Ito M, Nishikawa H.
    Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer.
    JCI Insight, 6:137365, 2021.
    DOI:10.1172/jci.insight.137365 PMID:33755600

  27. Watanabe S, Goto Y, Yasuda H, Kohno T, Motoi N, Ohe Y, Nishikawa H, Kobayashi SS, Kuwano K, Togashi Y.
    HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIs.
    Thorac Cancer, 12:631-642, 2021.

  28. Arakawa A, Ichikawa H, Kubo T, Motoi N, Kumamoto T, Nakajima M, Yonemori K, Noguchi E, Sunami K, Shiraishi K, Kakishima H, Yoshida H, Hishiki T, Kawakubo N, Kuroda T, Kiyokawa T, Yamada K, Yanaihara N, Takahashi K, Okamoto A, Hirabayashi S, Hasegawa D, Manabe A, Ono K, Matsuoka M, Arai Y, Togashi Y, Shibata T, Nishikawa H, Aoki K, Yamamoto N, Kohno T, Ogawa C.
    Vaginal Transmission of Cancer from Mothers with Cervical Cancer to Infants.
    N Engl J Med, 384:42-50, 2021.

  29. Kashima Y, Togashi Y (equally contribution), Fukuoka S, Kamada T, Irie T, Suzuki A, Nakamura Y, Shitara K, Minamide T, Yoshida T, Taoka N, Kawase T, Wada T, Inaki K, Chihara M, Ebisuno Y, Tsukamoto S, Fujii R, Ohashi A, Suzuki Y, Tsuchihara K, Nishikawa H, Doi T.
    Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens.
    Sci Rep, 11:341, 2021.

  30. Gu W, Ueda Y, Dansako H, Satoh S, Kato N.
    Antiviral mechanism of preclinical antimalarial compounds possessing multiple antiviral activities.
    FASEB BioAdv, 3(5):356-373, 2021.
    DOI:10.1096/fba.2020-00107　PMID:33977235

  31. Honobe A, Sakai K, Togashi Y, Ohnura T, Kawamura T, Nishio K, Inozume T.
    Heterogeneity in congenital melanocytic nevi contributes muliticentric melanomagenesis.
    J Dermatol Sci, 100:217-219, 2020.

  32. Hayashi H, Takiguchi Y, Minami H, Akiyoshi K, Segawa Y, Ueda H, Iwamoto Y, Kondoh C, Matsumoto K, Takahashi S, Yasui H, Sawa T, Onozawa Y, Chiba Y, Togashi Y, Fujita Y, Sakai K, Tomida S, Nishio K, Nakagawa K.
    Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.
    JAMA Oncol, 15:1-9, 2020.

  33. Nagasaki J, Togashi Y*, Sugawara T, Itami M, Yamauchi N, Yuda J, Sugano M, Ohara Y, Minami Y, Nakamae H, Hino M, Takeuchi M, Nishikawa H.
    The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classical Hodgkin lymphoma.
    Blood Adv, 4:4069-4082, 2020.

  34. Kawazoe A, Kuboki Y, Shinozaki E, Hara H, Nishina T, Komatsu Y, Yuki S, Wakabayashi M, Nomura S, Sato A, Kuwata T, Kawazu M, Mano H, Togashi Y, Nishikawa H, Yoshino T.
    Multicenter phase　1/2　trial　of　napabucasin　and　pembrolizumab　in　patients　with　metastatic　colorectal　cancer (EPOC1503).
    Clin Cancer Res, 26:5887-5894, 2020.

  35. Sato K, Mimaki S, Yamashita R, Togashi Y, Naito T, Udagawa H, Nakamura H, Katsumata S, Nakasone S, Tane K, Miyoshi T, Aokage K, Sugano M, Kojima M, Fujii S, Kuwata T, Ochiai A, Goto K, Tsuboi M, Tssuchihara K, Ishii G.
    Association between the mutational smoking signature and the immune microenvironment in lung adenocarcinoma.
    Lung Cancer, 147:12-20, 2020.

  36. Kumagai S, Togashi Y (equally contribution), Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y, Kochin V, Itahashi K, Maeda Y, Matsui S, Shibahara T, Yamashita Y, Irie T, Tsuge A, Fukuoka S, Kawazoe A, Udagawa H, Kirita K, Aokage K, Ishii G, Kuwata T, Nakama K, Kawazu M, Ueno T, Yamazaki N, Goto K, Tsuboi M, Mano H, Doi T, Shitara K and Nishikawa H.
    The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.
    Nat Immunol, 21:1346-1358, 2020.

  37. Kumagai S, Togashi Y*, Sakai S, Kawazoe A, Kawazu M, Ueno T, Sato E, Kuwata K, Kinoshita T, Yamamoto M, Nomura S, Tsukamoto T, Mano H, Shitara K, Nishikawa H.
    An oncogenic alteration creates a microenvironment that promotes tumor progression by conferring a metabolic advantage to regulatory T cells.
    Immunity, 53:187-203, 2020.

  38. Bando H, Kotani D, Tsushima T, Hara H, Kadowaki S, Kato K, Chin K, Yamaguchi K, Kageyama SI, Hojo H, Nakamura M, Tachibana H, Wakabayashi M, Fukutani M, Togashi Y, Fuse N, Nishikawa H, Kojima T.
    TENERGY: Multicenter Phase II Study of Atezolizumab Monotherapy Following Definitive Chemoradiotherapy With 5-FU Plus Cisplatin in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma.
    BMC Cancer, 20:336, 2020.

  39. Sasaki A, Nakamura Y, Togashi Y (equally contribution), Kuno H, Hojo H, Kageyama S, Nakamura N, Takashima K, Kadota T, Yoda Y, Mishima S, Sawada K, Kotani D, Kawazoe A, Kuboki Y, Taniguchi H, Kojima T, Doi T, Yoshino T, Yano T, Kobayashi T, Akimoto T, Nishikawa H, Shitara K.
    Enhanced Tumor Response to Radiotherapy After PD-1 Blockade in Metastatic Gastric Cancer.
    Gastric Cancer, 23:893-903, 2020.

  40. Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M, Yoshii T, Kotani D, Tamura H, Mikamoto Y, Hirano N, Wakabayashi M, Nomura S, Sato A, Kuwata T, Togashi Y, Nishikawa H, Shitara K.
    Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).
    J Clin Oncol, 38:2053-2061, 2020.

  41. Sugiyama E, Togashi Y (equally contribution), Takeuchi Y, Shinya S, Tada Y, Kataoka K, Tane K, Sato E, Ishii G, Goto K, Shintani Y, Okumura M, Tsuboi M, Nishikawa H.
    Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non–small cell lung cancer.
    Sci Immunol, 5:eaav3937, 2020.

  42. Umemoto K, Togashi Y (corresponding), Arai Y, Nakamura H, Takahashi S, Tanegashima T, Kato M, Nishikawa T, Sugiyama D, Kojima M, Gotohda N, Ikeda M, Shibata T, Nishikawa H.
    The potential application of PD-1 blockade therapy for early-stage biliary tract cancer.
    Int Immunol, 32:273-281, 2020.

  43. Kato N, Ueda Y, Sejima H, Gu W, Satoh S, Dansako H, Ikeda M, Shimotohno K.
    Study of multiple genetic variations caused by persistent hepatitis C virus replication in long-term cell culture.
    Arch Virol, 165(2):331-343, 2020.
    DOI:10.1007/s00705-019-04461-0　PMID:31832864

    Onomura D, Satoh S, Ueda Y, Dansako H, Kato N.
    Identification of ribavirin-responsive cis-elements for GPAM suppression in the GPAM genome.
    Biochem Biophys Res Commun, 533(1):148-154, 2020.
    DOI:10.1016/j.bbrc.2020.08.112　PMID:32933750

  44. Tokunaga A, Sugiyama D, Maeda Y, Warner AB, Panageas KS, Ito S, Togashi Y, Sakai C, Wolchok JD, Nishikawa H.
    Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids.
    J Exp Med, 216:2701-13, 2019.

  45. Haratani K, Hayashi H, Takahama T, Nakamura Y, Tomida S, Yoshida T, Chiba Y, Sawada T, Sakai K, Fujita Y, Togashi Y, Tanizaki J, Kawakami H, Ito A, Nishio K, Nakagawa K
    Clinical and Immune Profiling for Cancer of Unknown Primary Site.
    J Immunother Cancer, 7:25, 2019.

  46. Tanegashima T, Togashi Y*, Azuma K, Kawahara A, Ideguchi Ko, Sugiyama D, Kinoshita F, Akiba J, Kashiwagi E, Takeuchi A, Irie T, Tatsugami K, Hoshino T, Eto M, Nishikawa H.
    Immune suppression by PD-L2 against spontaneous and treatment-related antitumor immunity.
    Clin Cancer Res, 25:4808-4819, 2019.

  47. Kamada T, Togashi Y (equally contribution), Tay C, Ha D, Sasaki A, Nakamura Y, Sato E, Fukuoka S, Tada Y, Tanaka A, Kawazoe A, Kinoshita T, Shitara K, Sakaguchi S, Nishikawa H.
    PD-1+ regulatory T cells are activated by PD-1 blockade and contribute to hyperprogression of cancer.
    Proc Natl Acad Sci USA, 116:9999-10008, 2019.

  48. Inozume T, Yaguchi T, Ariyasu R, Togashi Y, Ohnuma T, Honobe A, Nishikawa H, Kawakami Y, Kawamura T.
    Analysis of the tumor reactivity of tumor-infiltrating lymphocytes in a metastatic melanoma lesion that lost MHC class I expression after anti-PD-1 therapy.
    J Invest Dermatol, 139:1490-1496, 2019.

  49. Watanabe S, Hayashi H, Haratani K, Shimizu S, Tanizaki J, Sakai K, Kawakami H, Yonesaka K, Tsurutani J, Togashi Y, Nishio K, Ito A, Nakagawa K.
    Mutational activation of the EGFR down-regulates MHC class I expression via the ERK in non–small cell lung cancer.
    Cancer Sci, 110:52-60, 2019.

  50. Kawazoe A, Shitara K, Kuboki Y, Bando H, Kojima T, Yoshino T, Ohtsu A, Ochiai A, Togashi Y, Nishikawa H, Doi T, Kuwata T.
    Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer.
    Gastric Cancer, 22:69-76, 2019.

  51. Togashi Y, Shitara K, Nishikawa H.
    Treg cells in cancer immunosuppression - Implications for anticancer therapy.
    Nat Rev Clin Oncol, 16:356-371, 2019.

  52. Dansako H, Imai H, Ueda Y, Satoh S, Shimotohno K, Kato N.
    High‐level expression of STING restricts susceptibility to HBV by mediating type III IFN induction.
    FASEB BioAdvances, 1(2):67-80, 2019.

  53. Ueno M, Nogawa M, Siddiqui R, Watashi K, Wakita T, Kato N, Ikeda M, Okimura T, Isaka S, Oda T, Ariumi Y.
    Acidic polysaccharides isolated from marine algae inhibit the early step of viral infection.
    Int J Biol Macromol, 124:282-290, 2019.

  54. Satoh S, Onomura D, Ueda Y, Dansako H, Honda M, Kaneko S, Kato N.
    Ribavirin-induced downregulation of CCAAT/enhancer-binding protein α leads to suppression of lipogenesis.
    Biochem J, 476(1):137-149, 2019.

  55. Ueda Y, Gu W, Dansako H, Nishitsuji H, Satoh S, Shimotohno K, Kato N.
    A new hepatoma cell line exhibiting high susceptibility to hepatitisB virus infection.
    Biochem Biophys Res Commun, 515(1):156-162, 2019.

  56. Tada Y, Togashi Y (equally contribution), Kotani D, Kuwata T, Sato E, Kawazoe A, Doi T, Wada H, Nishikawa H, Shitara K.
    Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment.
    J Immunother Cancer, 6:106, 2018.

  57. Dansako H, Imai H, Ueda Y, Satoh S, Wakita T, Kato N.
    ULBP1 is induced by hepatitis C virus infection and is the target of the NK cell-mediated
    innate immune response in human hepatocytes.
    FEBS Open Bio, 8(3):361-371, 2018.

  58. Kuwashiro T, Iwane S, Jinghe X, Matsuhashi S, Eguchi Y, Anzai K, Fujimoto K, Mizuta T, Sakamoto N, Ikeda M, Kato N, Ozaki I.
    Regulation of interferon signaling and HCV‑RNA replication by extracellular matrix.
    Int J Mol Med, 42:957-65, 2018.

  59. Murakami Y, Sugiyama K, Ebinuma H, Nakamoto N, Ojiro K, Chu P-S, Taniki N, Saito Y, Teratani T, Koda Y, Suzuki T, Saito K, Fukasawa M, Ikeda M, Kato N, Kanai T, Saito H.
    Dual effects of the Nrf2 inhibitor for inhibition of hepatitis C virus and hepatic cancer cells.
    BMC Cancer, 18(1):680, 2018.

  60. Ueda Y, Gu W, Dansako H, Kim HS, Yoshizaki S, Okumura N, Ishikawa T, Nishitsuji H, Kato F, Hishiki T, Satoh S, Ishii K, Masuda M, Shimotohno K, Ikeda M, Kato N.
    Multiple antiviral activities of the antimalarial and anti-hepatitis C drug candidates N-89 and N-251.
    Biochem Biophys Rep, 15:1-6, 2018.

  61. Imai H, Dansako H, Ueda Y, Satoh S, Kato N.
    Daunorubicin, a topoisomerase II poison, suppresses viral production of hepatitis B virus by inducing cGAS-dependent innate immune response.
    Biochem Biophys Res Commun, 504(4):672-8, 2018.

  62. Banno E, Togashi Y, de Velasco MA, Mizukami T, Nakamura Y, Terashima M, Sakai K, Fujita Y, Kamata K, Kitano M, Kudo M, Nishio K.
    Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib.
    Int J Oncol, 50:2049-58, 2017.

  63. Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, Hayashi K, Tomida S, Chiba Y, Yonesaka K, Nonagase Y, Takahama T, Tanizaki J, Tanaka K, Yoshida T, Tanimura K, Takeda M, Yoshioka H, Ishida T, Mitsudomi T, Nishio K, Nakagawa K.
    Tumor Immune Microenvironment and Nivolumab Efficacy in EGFR Mutation Positive Non–Small Cell Lung Cancer Based on T790M Status after Disease Progression During EGFR-TKI Treatment.
    Ann Oncol, 28:1532-9, 2017.

  64. Chiba M, Togashi Y, Bannno E, Kobayashi Y, Nakamura Y, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K.
    Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.
    BMC Cancer, 17:281, 2017.

  65. Kobayashi Y, Azuma K, Nagai H, Kim YH, Togashi Y, Sesumi Y, Chiba M, Shimoji M, Sato K, Tomizawa K, Takemoto T, Nishio K, Mitsudomi T.
    Characterization of EGFR T790M, L792F, and C797S mutations as mechanisms of acquired resistance to afatinib in lung cancer.
    Mol Cancer Ther, 16:357-364, 2017.

  66. Mizukami T, Togashi Y, Naruki S, Banno E, Terashima M, De Velasco MA, Sakai K, Yoneshige A, Hayashi H, Fujita Y, Tomida S, Nakajima TE, Fujino T, Boku N, Ito A, Nakagawa K, Nishio K.
    Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: a subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies.
    Mol Carcinog, 56:106-117, 2017.

  67. Togashi Y, Nishikawa H.
    Suppression from beyond the grave.
    Nat Immunol, 18:1285-1286, 2017.

  68. Togashi Y and Nishikawa H.
    Regulatory T cells: molecular and cellular basis for immunoregulation.
    Curr Top Microbiol Immunol, 410:3-27, 2017.

  69. Ueda Y, Dansako H, Sato S, Kim HS, Wataya Y, Doi H, Ikeda M, Kato N.
    Evaluation of preclinical antimalarial drugs, which can overcome direct-acting antivirals-resistant hepatitis C viruses, using the viral reporter assay systems.
    Virus Res, 235:37-48, 2017.

  70. Satoh S, Mori K, Onomura D, Ueda Y, Dansako H, Honda M, Kaneko S, Ikeda M, Kato N.
    Ribavirin suppresses hepatic lipogenesis through inosine monophosphate dehydrogenase inhibition: involvement of adenosine monophosphate-activated protein kinase-related kinases and retinoid X receptor α.
    Hepatol Commun, 1(6):550-63, 2017.

  71. Machitani M, Sakurai F, Wakabayashi K, Nakatani K, Tachibana M, Kato N, Fujiwara T, Mizuguchi H.
    Suppression of oncolytic adenovirus-mediated hepatotoxicity by liver-specific inhibition of NF-κB.
    Mol Ther Oncolytics, 7:76-85, 2017.

  72. Chiba M, Togashi Y, Tomida S, Mizuuchi H, Nakamura Y, Banno E, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K.
    MEK inhibitors against MET-amplified non-small cell lung cancer.
    Int J Oncol, 49:2236-2244, 2016.

  73. Hibi M, Kaneda H, Tanizaki J, Sakai K, Togashi Y, Terashima M, De Velasco MA, Fujita Y, Banno E, Nakamura Y, Takeda M, Ito A, Mitsudomi T, Nakagawa K, Okamoto I, Nishio K.
    FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.
    Cancer Sci, 107:1667-76, 2016.

  74. Banno E, Togashi Y, Nakamura Y, Chiba M, Kobayashi Y, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K.
    Sensitivities to various EGFR-TKIs of uncommon EGFR mutations L861Q and S768I: what is the optimal EGFR-TKI?
    Cancer Sci, 107:1134-40, 2016.

  75. Nakamura Y, Togashi Y, Nakahara H, Tomida S, Banno E, Terashima M, Hayashi H, De Velasco MA, Sakai K, Fujita S, Okegawa T, Nutahara K, Hamada S, Nishio K.
    Afatinib against esophageal or head-and-neck squamous cell carcinoma: significance of activating oncogenic HER4 mutations in HNSCC.
    Mol Cancer Ther, 15:1988-97, 2016.

  76. Terashima M, Togashi Y, Sato K, Mizuuchi H, Sakai K, Suda K, Nakamura Y, Banno E, Hayashi H, De Velasco MA, Fujita Y, Tomida S, Mitsudomi T, Nishio K.
    Functional analyses of mutations in receptor tyrosine kinase genes in non-small cell lung cancer: double-edged sword of DDR2.
    Clin Cancer Res, 22:3663-71, 2016.

  77. Tanizaki J, Banno E, Togashi Y, Hayashi H, Sakai K, Takeda M, Kaneda H, Nishio K, Nakagawa K.
    Durable response to afatinib in lung cancer with concomitant EGFR uncommon mutations and KRAS mutation.
    Lung Cancer, 101:44515, 2016.

  78. Dansako H, Ueda Y, Okumura N, Satoh S, Sugiyama M, Mizokami M, Ikeda M, Kato N.
    The cyclic GMP-AMP synthetase-STING signaling pathway is required for
    both the innate immune response
    against HBV and the suppression of HBV assembly.
    The FEBS J, 283(1):144-56, 2016.

  79. Sejima H, Satoh S, Dansako H, Honda M, Kaneko S, Ikeda M, Kato N.
    Molecular mechanism underlying the suppression of CPB2 expression caused by
    persistent hepatitis C virus RNA replication.
    Acta Med Okayama, 70(2):75-88, 2016.

  80. Takeda M, Ikeda M, Satoh S, Dansako H, Wakita T, Kato N.
    Rab13 is involved in the entry step of hepatitis C virus infection.
    Acta Med Okayama, 70(2):111-8, 2016.

  81. Mostafa AS, El Bialy SA, Bayoumi WA, Ueda Y, Ikeda M, Kato N, Abdelal AM.
    Synthesis and in vitro activity of pyrrolo[3,4-d]pyrimidine-2,5-diones as potential
    non-nucleoside HCV inhibitors.
    Curr Enzym Inhib, 12(2):170-6, 2016.

  82. Nitta S, Asahina Y, Matsuda M, Yamada N, Sugiyama R, Masaki T, Suzuki R, Kato N,
    Watanabe M, Wakita T, Kato T.
    Effects of resistance-associated NS5A mutations in hepatitis C virus on viral production and
    susceptibility to antiviral reagents.
    Sci Rep, 6:34652, 2016.

  83. Togashi Y, Mizuuchi H, Tomida S, Terashima M, Hayashi H, Nishio K, Mitsudomi T.
    MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor.
    Lung Cancer, 90:590-597, 2015.

  84. Shinke H, Masuda S, Togashi Y, Ikemi Y, Ozawa A, Sato T, Kim YH, Mishima M, Ichimura T, Bonventre JV, Matsubara K.
    Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients.
    Cancer Chemother Pharmacol, 76:989-96, 2015.

  85. Yoshioka Y, Togashi Y, Chikugo T, Kogita A, Taguri M, Terashima M, Mizukami T, Hayashi H, Sakai K, De Velasco MA, Tomida S, Fujita Y, Tokoro T, Ito A, Okuno K, Nishio K.
    Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinoma.
    Cancer, 121:4359-68, 2015.

  86. Kobayashi Y, Togashi Y, Yatabe Y, Mizuuchi H, Jangchul P, Kondo C, Shimoji M, Sato K, Suda K, Tomizawa K, Takemoto T, Hida, T, Nishio K, Mitsudomi T.
    EGFR exon 18 mutations in lung cancer: molecular predictors of augmented sensitivity to afatinib and neratinib as compared with first or third generation TKIs.
    Clin Cancer Res, 21:5305-13, 2015.

  87. Mizukami T, Togashi Y, Sogabe S, Banno E, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Nakajima TE, Boku N, Nishio K.
    EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.
    Int J Oncol, 47:499-505, 2015.

  88. Togashi Y, Mizuuchi H, Kobayashi Y, Hayashi H, Terashima M, Sakai K, Bannno E, Mizukami T, Nakamura Y, de Velasco MA, Fujita Y, Tomida S, Mitsudomi T, Nishio K.
    An activating ALK gene mutation in ALK IHC-positive/FISH-negative non-small cell lung cancer.
    Ann Oncol, 26:1800-1801, 2015.

  89. Yamaue H, Tsunoda T, Tani M, Miyazawa M, Yamao K, Mizuno N, Okusaka T, Ueno H, Boku N, Fukutomi A, Ishii H, Ohkawa S, Furukawa M, Maguchi H, Ikeda M, Togashi Y, Nishio K, Ohashi Y.
    Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer; PEGASUS-PC Study.
    Cancer Sci, 106:883-890, 2015.

  90. Sakai K, Tsurutani J, Yamanaka T, Yoneshige A, Ito A, Togashi Y, de Velasco MA, Terashima M, Fujita Y, Tomida S, Tamura T, Nakagawa K, Nishio K.
    Extended RAS and BRAF mutation analysis using next-generation sequencing.
    PLoS One, 10:e0121891, 2015.

  91. Fujita S, Masago K, Takeshita J, Togashi Y, Hata A, Kaji R, Kokubo M, Katakami N.
    Multiple primary malignancies in patients with non-small cell lung cancer.
    Intern Med, 54:325-331, 2015.

  92. Sakai K, Yoneshige A, Ito A, Ueda Y, Kondo S, Nobumasa H, Fujita Y, Togashi Y, Terashima M, De Velasco MA, Tomida S, Nishio K.
    Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer.
    Springerplus, 4:7, 2015.

  93. Banno E, Togashi Y, Kobayashi Y, HayashiH, Mitsudomi T, Nishio K.
    Afatinib is especially effective aganst non-small cell lung cancer carrying an EGFR exon 19 deletion.
    Anticancer Res, 35:2005-2008, 2015.

  94. Togashi Y, Hayashi H,　Oakamoto K, Fumita S, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Nakagawa K, Nishio K.
    Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal.
    Lung Cancer, 88:16-23, 2015.

  95. Kogita A, Yoshioka Y, Sakai K, Togashi Y, Sogabe S, Nakai T, Okuno K, Nishio K.
    Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis.
    Biochem Biophys Res Commun, 458:52-56, 2015.

  96. Kogita A, Togashi Y, Hayashi H, Sogabe S, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Takeyama Y, Okuno K, Nakagawa K, Nishio K.
    Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.
    Int J Oncol, 46:1025-30, 2015.

  97. Togashi Y, Kogita A, Sakamoto H, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Kitano M, Okuno K, Kudo M, Nishio K.
    Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer.
    Cancer Lett, 356:819-27, 2015.

  98. Togashi Y, Hayashi H,　Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Nakagawa K, Nishio K.
    Inhibition of beta-catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small cell lung　cancer with a T790M mutation.
    J Thorac Oncol, 10:93-101, 2015.

  99. Ueki N, Matsuo Y, Togashi Y, Kubo T, Shibuya K, Iizuka Y, Mizowaki T, Togashi K, Mishima M, Hiraoka M.
    Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer.
    J Thorac Oncol, 10:116-25, 2015.

  100. Hiramoto H, Dansako H, Takeda M, Satoh S, Wakita T, Ikeda M, Kato N.
    Annexin A1 negatively regulates viral RNA replication of hepatitis C virus.
    Acta Medica Okayama, 69(2):71-8, 2015

  101. Satoh S, Mori K, Ueda Y, Sejima H, Dansako H, Ikeda M, Kato N.
    Establishment of hepatitis C virus RNA-replicating cell lines possessing ribavirin-resistant phenotypes.
    PLoS ONE, 10(2):e0118313, 2015

  102. Murakami Y, Itami S, Eguchi Y, Mizutani T, Aoki E, Ohgi T, Kuroda M, Ochiya T, Kato N, Suzuki H, Kawada N.
    Control of HCV replication with iMIRs, a novel anti-RNAi agent.
    Molecular Ther Nucleic Acids, 4(1):e219, 2015

  103. Okumura N, Ikeda M, Satoh S, Dansako H, Sugiyama M, Mizokami M, Kato N.
    Negative regulation of hepatitis B virus replication by forkhead box protein A in human hepatoma cells.
    FEBS Letters, 589(10):1112-8, 2015

  104. Kasai H, Kawakami K, Yokoe H, Yoshimura K, Matsuda M, Yasumoto J, Maekawa S, Yamashita A, Tanaka T, Ikeda M, Kato N, Okamoto T, Matsuura Y, Sakamoto N, Enomoto N, Takeda S, Fujii H, Tsubuki M, Kusunoki M, Moriishi K.
    Involvement of FKBP6 in hepatitis C virus replication.
    Sci Rep, 5:16699, 2015.
  105. Sogabe S, Togashi Y (equally contribution), Kato H, Kogita A, Mizukami T, Sakamoto Y, Banno E, Terashima M, Hayashi H, De Velasco MA, Sakai K, Fujita Y, Tomida S, Yasuda T, Takeyama Y, Okuno K, Nishio K.
    MEK inhibitor for gastric cancer with MEK1 mutations.
    Mol Cancer Ther, 13:3098-106, 2014.

  106. Terashima M, Sakai K, Togashi Y, Hayashi H, De Velasco MA, Tsurutani J, Nishio K.
    Synergistic antitumor effect of S-1 with eribulin in vitro and in vivo for tripple-negative breast cancer cell lines.
    Springerplus, 3:417, 2014.

  107. Kogita A, Togashi Y, Hayashi H, Sogabe S, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Takeyama Y, Okuno K, Nakagawa K, Nishio K.
    Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epitherial-mesenchymal transition.
    Int J Oncol, 45:1430-1436, 2014.

  108. Terashima M, Fujita Y, Togashi Y, Sakai K, De Velasco MA, Tomida S, Nishio K.
    KIAA1199 interacts with glycogen phosphorylase kinase β-subunit (PHKB) to promote glycogen breakdown and cancer cell survival.
    Oncotarget, 5:7040-7050, 2014.

  109. Togashi Y, Arao T, Kato H, Matsumoto K, Terashima M, Hayashi H, de Velasco MA, Fujita Y, Kimura H, Yasuda T, Shiozaki H, Nishio K.
    Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS production.
    Oncotarget, 5:2962-2973, 2014.

  110. Togashi Y, Sakamoto H, Hayashi H, Terashima M, de Velasco MA, Fujita Y, Kodera Y, Sakai K, Tomida S, Kitano M, Ito A, Kudo M, Nishio K.
    Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer.
    Mol Cancer, 13:126, 2014.

  111. Hayashi H, Arao T, Matsumoto K, Kimura H, Togashi Y, Hirashima Y, Horita Y, Iwasa S, Okita NT, Honma Y, Takashima A, Kato K, Hamaguchi T, Shimada Y, Nakagawa K, Nishio K, Yamada Y.
    Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma.
    Oncotarget, 5:2588-2595, 2014.

  112. Fujita Y, Koinuma S, De Velasco MA, Bolz J, Togashi Y, Terashima M, Hayashi H, Matsuo T, Nishio K.
    Melanoma transition is frequently accompanied by a loss of cytoglobin expression in melanocytes: a novel expression site of cytoglobin.
    PLoS One, 9:e94772, 2014.

  113. Okamoto M, Oshiumi H, Azuma M, Kato N, Matsumoto M, Seya T.
    IPS-1 is essential for type III interferon production by hepatocytes and dendritic cells in response to hepatitis C virus infection.
    J Immunol, 192(6):2770-7, 2014

  114. Kato N, Sejima H, Ueda Y, Mori K, Satoh S, Dansako H, Ikeda M.
    Genetic characterization of hepatitis C virus in long-term RNA replication using Li23 cell culture systems.
    PLoS ONE, 9(3):e91156, 2014

  115. Ueda Y, Mori K, Satoh S, Dansako H, Ikeda M, Kato N.
    Anti-HCV activity of the Chinese medicinal fungus Cordyceps militaris.
    Biochem Biophys Res Commun, 447(2):341-5, 2014

  116. Dansako H, Hiramoto H, Ikeda M, Wakita T, Kato N.
    Rab18 is required for viral assembly of hepatitis C virus through trafficking of the core protein to lipid droplets.
    Virology, 462-463:166-74, 2014

  117. Matsuno K, Ueda Y, Fukuda M, Onoda K, Waki M, Ikeda M, Kato N, Miyachi H.
    Synthesis and inhibitory activity on hepatitis C virus RNA replication of 4-(1,1,1,3,3,3-hexafluoro-2-hydroxy-2-propyl)aniline analogs.
    Bioorg Med Chem Lett, 27(17):4276-80, 2014

  118. Matsuda M, Suzuki R, Kataoka C, Watashi K, Aizaki H, Kato N, Matsuura Y, Suzuki T, Wakita T.
    Alternative endocytosis pathway for productive 1 entry of hepatitis C virus.
    J Gen Virol, 95(12):2658-67, 2014

  119. Hara Y, Yanatori I, Ikeda M, Kiyokage E, Nishina S, Tomiyama Y, Toida K, Kishi F, Kato N, Imamura M, Chayama K, Hino K.
    Hepatitis C virus core protein suppr 1 esses mitophagy by interacting with Parkin in the context of mitochondrial depolarization.
    Amer J Pathol, 184(11):3026-39, 2014

  120. Shimada H, Haraguchi K, Hotta K, Miyaike T, Kitagawa Y, Tanaka H, Kaneda R, Abe H, Shuto S, Mori K, Ueda Y, Kato N, Snoeck R, Andrei G, Balzarini J.
    Synthesis of 3',4'-difluoro-3'-deoxyribonucleosides and its evaluation of the biological activities: Discovery of a novel type of anti-HCV agent 3',4'-difluorocordycepin.
    Bioorg Med Chem, 22(21):6174-82, 2014

  121. Hayashi H, Arao T, Togashi Y, Kato H, Fujita Y, De Velasco MA, Kimura H, Matsumoto K, Tanaka K, Okamoto I, Ito A, Yamada Y, Nakagawa K, Nishio K.
    The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer.
    Oncogene, 34:199-208, 2015.

  122. Togashi Y　(corresponding author), Hayashi H, Nakagawa K, Nishio K.
    Clinical utility of erlotinib for the treatment of non-small cell lung cancer in Japanese patients: current evidence.
    Drug Des Devel Ther, 8:1037-1064, 2014.

  123. Fukudo M, Ikemi Y, Togashi Y, Masago K, Kim YH, Mio T, Terada T, Teramukai S, Mishima M, Inui KI, Katsura T.
    Population Pharmacokinetics/Pharmacodynamics of Erlotinib and Pharmacogenomic Analysis of Plasma and Cerebrospinal Fluid Drug Concentrations in Japanese Patients with Non-Small Cell Lung Cancer.
    Clin Pharmacokinet, 52:593-609, 2013.

  124. Kim YH, Okuda C, Sakamori Y, Masago K, Togashi Y, Mishima M.
    Continuous morphine infusion for end-stage lung cancer patients.
    Oncol Lett, 5:972-974, 2013.

  125. Togashi Y, Masago K, Ito Y, Sakamori Y, Okuda C, Fukuhara A, Nagai H, Kim YH, Mishima M.
    Pneumocystis jiroveci pneumonia and colonization in patients with advanced lung cancer.
    Oncol Lett, 5:601-604, 2013.

  126. Masago K, Togashi Y, Fujita S, Nagai H, Sakamori Y, Okuda C, Kim YH, Mishima M.
    Effect of the BCL2 Gene Polymorphism on Survival in Advanced-Stage Non-Small Cell Lung Cancer Patients Who Received Chemotherapy.
    Oncology, 84:214-218, 2013.

  127. Tanaka T, Kuroda K, Ikeda M, Wakita T, Kato N, Makishima M.
    Hepatitis C virus NS4B targets lipid droplets through hydrophobic residues in the amphipathic helices.
    J Lipid Res, 54:881-92, 2013

  128. Kuroki M, Ariumi Y, Hijikata M, Ikeda M, Dansako H, Wakita T, Shimotohno K, Kato N.
    PML tumor suppressor protein is required for HCV production.
    Biochem Biophys Res Commun, 430:592-7, 2013

  129. Dansako H, Yamane D, Welsch C, McGivern DR, Hu F, Kato N, Lemon SM.
    Class A scavenger receptor 1 (MSR1) restricts hepatitis C virus replication by mediating toll-like receptor 3 recognition of viral RNAs produced in neighboring cells.
    PLoS Pathogens, 9(5):e1003345, 2013

  130. Mori K, Hiraoka O, Ikeda M, Ariumi Y, Hiramoto A, Wataya Y, Kato N.
    Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin.
    Hepatology, 58(4):1236-44, 2013

  131. Shinohara Y, Imajo K, Yoneda M, Tomeno W, Ogawa Y, Kirikoshi H, Funakoshi K, Ikeda M, Kato N, Nakajima A, Saito S.
    Unfolded protein response pathways regulate Hepatitis C virus replication via modulation of autophagy.
    Biochem Biophys Res Commun, 432:326-32, 2013

  132. Tani J, Shimamoto S, Mori K, Kato N, Moriishi K, Matsuura Y, Tokumitsu H, Tsuchiya M, Fujimoto T, Kato K, Miyoshi H, Masaki T, Kobayashi R.
    Ca2+/S100 proteins regulate HCV virus NS5A-FKBP8/FKBP38 interaction and HCV virus RNA replication.
    Liver Int, 33(7):1008-18, 2013

  133. Tanaka T, Kuroda K, Ikeda M, Kato N, Shimizu K, Makishima M.
    Direct targeting of proteins to lipid droplets demonstrated by time-lapse live cell imaging.
    J Bioscience and Bioengineering, 116(5):620-3, 2013

  134. Ding Q, Cao X, Lu J, Huang B, Liu YJ, Kato N, Shu HB, Zhong J.
    Hepatitis C virus NS4B blocks the interaction of STING and TBK1 to evade host innate immunity.
    J Hepatol, 59(1):52-8, 2013

  135. Shinohara Y, Imajo K, Yoneda M, Tomeno W, Ogawa Y, Fujita K, Kirikoshi H, Takahashi J, Funakoshi K, Ikeda M, Kato N, Nakajima A, Saito S.
    Hepatic triglyceride lipase plays an essential role in changing the lipid metabolism in genotype 1b hepatitis C virus replicon cells and hepatitis C patients.
    Hepatol Res, 43(11):1190-8, 2013

  136. Sato A, Saito Y, Sugiyama K, Sakasegawa N, Muramatsu T, Fukuda S, Yoneya M, Kimura M, Ebinuma H, Hibi T, Ikeda M, Kato N, Saito H.
    Suppressive effect of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on hepatitis C virus replication via epigenetic changes in host cells.
    J Cell Biochem, 114(9):1987-96, 2013

  137. Ueda Y, Takeda M, Mori K, Dansako H, Wakita T, Kim HS, Sato A, Wataya Y, Ikeda M, Kato N.
    New preclinical antimalarial drugs potently inhibit hepatitis C virus genotype 1b RNA replication.
    PLoS ONE, 8(8):e72519, 2013

  138. Ban S, Ueda Y, Ohashi M, Matsuno K, Ikeda M, Kato N, Miyachi H.
    Peroxisome proliferator-activated receptor delta antagonists inhibit hepatitis C virus RNA replication.
    Bioorg Med Chem Letters, 23(17):4774-8, 2013

  139. Shen H, Yamashita A, Nakakoshi M, Yokoe H, Sudo M, Kasai H, Tanaka T, Fujimoto Y, Ikeda M, Kato N, Sakamoto N, Shindo H, Maekawa S, Enomoto N, Tsubuki M, Moriishi K.
    Inhibitory effects of caffeic acid phenethyl ester derivatives on replication of hepatitis C virus.
    PLoS ONE, 8(12):e82299, 2013

  140. Togashi Y*, Masago K, Masuda S, Mizuno T, Fukudo M, Ikemi Y, Sakamori Y, Nagai H, Kim YH, Katsura T, Mishima M.
    Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.
    Cancer Chemother Pharmacol, 70:399-405, 2012.

  141. Kim YH, Hirabayashi M, Togashi Y, Hirano K, Tomii K, Masago K, Kaneda T, Yoshimatsu H, Otsuka K, Mio T, Tomioka H, Suzuki Y, Mishima M.
    Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
    Cancer Chemother Pharmacol, 70:271-276, 2012.

  142. Nagai H, Yasuda H, Hatachi Y, Xue D, Sasaki T, Yamaya M, Sakamori Y, Togashi Y, Masago K, Ito I, Kim YH, Mio T, Mishima M.
    Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO‑cGMP signaling in lung adenocarcinoma cells in vitro and in vivo.
    Int J Oncol, 41:24-30, 2012.

  143. Togashi Y*, Masago K, Kubo T, Fujimoto D, Sakamori Y, Nagai H, Kim YH, Togashi K, Mishima M.
    Association between vascular-poor area of primary tumors and epidermal growth factor receptor gene status in advanced lung adenocarcinoma.
    Med Oncol, 29:3169-3175, 2012.

  144. Sakamori Y, Masago K, Ohmori K, Togashi Y, Nagai H, Okuda C, Kim YH, Ichiyama S, Mishima M.
    Increase in circulating endothelial progenitor cells predicts response in patients with advanced non-small cell lung cancer.
    Cancer Sci, 103:1065-1070, 2012.

  145. Kim YH, Sumiyoshi S, Hashimoto S, Masago K, Togashi Y, Sakamori Y, Okuda C, Mio T, Mishima M.
    Expressions of Insulin-Like Growth Factor Receptor-1 and Insulin-Like Growth Factor Binding Protein 3 in Advanced Non-Small-Cell Lung Cancer.
    Clin Lung Cancer, 13:385-390, 2012.

  146. Togashi Y*, Masago K, Handa T, Tanizawa K, Okuda C, Sakamori Y, Nagai H, Kim YH, Mishima M.
    Prognostic Significance of Preexisting Interstitial Lung Disease in Japanese Patients with Small-Cell Lung Cancer.
    Clin Lung Cancer, 13:304-311, 2012.

  147. Masago K, Togashi Y, Fujita S, Sakamori Y, Okuda C, Kim YH, Mio T, Mishima M.
    Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib.
    Med Oncol, 29:1614-1621, 2012.

  148. Irisa K, Masago K, Togashi Y, Fujita S, Hatachi Y, Fukuhara A, Sakamori Y, Kim YH, Mio T, Mishima M.
    Significance of pretreatment comorbidities in elderly patients with advanced non-small-cell lung cancer treated with chemotherapy or epidermal growth factor receptor-tyrosine kinase inhibitor.
    Med Oncol, 29:185-192, 2012.

  149. Kawaji T, Shiomi H, Togashi Y, Gunji D, Imai M, Doi T, Kimura T.
    Coronary air embolism and cardiogenic shock during computed tomography-guided needle biopsy of the lung.
    Circulation, 126:e195-197, 2012.

  150. Togashi Y*, Masago K, Hamatani Y, Sakamori Y, Nagai H, Kim YH, Mishima M.
    Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: A case report and review of the literature.
    Lung Cancer, 77:464-468, 2012.

  151. Mori K, Ueda Y, Ariumi Y, Dansako H, Ikeda M, Kato N.
    Development of a drug assay system with hepatitis C virus genome derived from a patientwith acute hepatitis C.
    Virus Genes, 44(3):374-81, 2012

  152. Iikura M, Furihata T, Mizuguchi M, Nagai M, Ikeda M, Kato N, Tsubota A, Chiba K.
    ENT1, a ribavirin transporter, plays a pivotal role in antiviral efficacy of ribavirin in a hepatitis C virus replication cell system.
    Antimicrob Agents Chemother, 56(3):1407-13, 2012

  153. Takeshita S, Ichikawa T, Taura N, Miyaaki H, Matsuzaki T, Otani M, Muraoka T, Akiyama M, Miuma S, Ozawa E, Ikeda M, Kato N, Isomoto H, Takeshima F, Nakao K.
    Geranylgeranylacetone has anti-hepatitis C virus activity via activation of mTOR in human hepatoma cells.
    J Gastroenterol, 47(2):195-202, 2012

  154. Takeda M, Ikeda M, Ariumi Y, Wakita T, Kato N.
    Development of hepatitis C virus production reporter assay systems using two different hepatoma cell lines.
    J Gen Virol, 93(7):1422-31, 2012

  155. Marozin S, Altomonte J, Apfel S, Dinh P, Toni ED, Rizzani A, Nussler A, Kato N, Schmid R, Pattnaik A, Ebert, O.
    Post-translational modification of VSV glycoprotein, but not JNK inhibition, is the antiviral mechanism of SP600125.
    J Virol, 86(9):4844-55, 2012

  156. Yamashita A, Salam KA, Furuta A, Matsuda Y, Fujita O, Tani H, Fujita Y, Fujimoto Y, Ikeda M, Kato N, Sakamoto N, Maekawa S, Enomoto N, Nakakoshi M, Tsubuki M, Sekiguchi Y, Tsuneda S, Akimitsu N, Noda N, Tanaka J, Moriishi K.
    Inhibition of hepatitis C virus replication and viral helicase byethyl acetate extract of the marine feather star Alloeocomatella polycladia.
    Mar Drugs, 10:744-761, 2012

  157. Sejima H, Mori K, Ariumi Y, Ikeda M, Kato N.
    Identification of host genes showing differential expression profiles with cell-based long-term replication of hepatitis C virus RNA.
    Virus Res, 167(1):74-85, 2012

  158. Takeda M, Ikeda M, Mori K, Yano M, Ariumi Y, Dansako H, Wakita T, Kato N.
    Raloxifene inhibits hepatitis C virus infection and replication.
    FEBS Open Bio, 2:279-83, 2012

  159. Koike K, Takaki A, Kato N, Ouchida M, Kanzaki H, Yasunak T, Shiraha H, Miyake Y, Yamamoto K.
    Eradication of hepatitis C virus subgenomic replicon by interferon results in aberrant retinol related protein expression.
    Acta Med Okayama, 66(6):461-8., 2012

  160. Fujimoto Y, Salam KA, Furuta A, Matsuda Y, Fujita O, Tani H, Ikeda M, Kato N, Sakamoto N, MaekawaS, Enomoto N, de Voogd NJ, Nakakoshi M, Tsubuki M, Sekiguchi Y, Tsuneda S, Akimitsu N, Noda N, Yamashita A, Tanaka J, Moriishi K.
    Inhibition of both protease and helicase activities of hepatitis 1 C virus NS3 by an ethyl acetate extract of marine sponge Amphimedon sp.
    PLoS ONE, 7:e48685, 2012

  161. Masago K, Fujita S, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, Nagai H, Irisa K, Sakamori Y, Mio T, Mishima M.
    Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer.
    Oncol Rep, 26:795-803, 2011.

  162. Masago K, Togashi Y, Fukudo M, Terada T, Irisa K, Sakamori Y, Kim YH, Mio T, Inui KI, Mishima M.
    Plasma and Pleural Fluid Pharmacokinetics of Erlotinib and its Active Metabolite OSI-420 in Patients with Non-Small-Cell Lung Cancer with Pleural Effusion.
    Clin Lung Cancer, 13:307-312, 2011.

  163. Togashi Y*, Masago K, Fukudo M, Tsuchido Y, Okuda C, Kim YH, Ikemi Y, Sakamori Y, Mio T, Katsura T, Mishima M.
    Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation.
    Cancer Chemother Pharmacol, 68:1089-1092, 2011.

  164. Togashi Y, Masago K, Fujita S, Hatachi Y, Fukuhara A, Nagai H, Sakamori Y, Kim YH, Mio T, Mishima M.
    Differences in adverse events between 250mg daily gefitinib and 150mg daily erlotinib in Japanese patients with non-small cell lung cancer.
    Lung Cancer, 74:98-102, 2011.

  165. Kim YH, Masago K, Togashi Y, Sakamori Y, Okuda C, Mio T, Mishima M.
    EGFR mutation: Significance as a stratification factor in the era of molecular-targeted therapy.
    Oncol Lett, 2:383-387, 2011.

  166. Masago K, Fujita S, Togashi Y, Irisa K, Sakamori Y, Hatachi Y, Fukuhara A, Nagai H, Kim YH, Mio T, Mishima M.
    Association between brain natriuretic peptide and distant metastases in advanced non-small cell lung cancer patients.
    Oncol Lett, 2:253-256, 2011.

  167. Masago K, Fujita S, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, Nagai H, Sakamori Y, Mio T, Mishima M.
    Clinicopathologic Factors Affecting the Progression-Free Survival of Patients With Advanced Non-Small-Cell Lung Cancer After Gefitinib Therapy.
    Clin Lung Cancer, 12:56-61, 2011.

  168. Togashi Y, Masago K, Fujita S, Kim YH, Sakamori Y, Hatachi Y, Fukuhara A, Nagai H, Mio T, Mishima M.
    Association of the transforming growth factor ß1 promoter polymorphism, C-509T, with smoking status and survival in advanced non-small cell lung cancer.
    Oncol Rep, 25:377-382, 2011.

  169. Togashi Y, Masago K, Kubo T, Sakamori Y, Kim YH, Hatachi Y, Fukuhara A, Mio T, Togashi K, Mishima M.
    Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma.
    Cancer, 117:819-825, 2011.

  170. Okuda C, Kim YH, Takeuchi K, Togashi Y, Masago K, Sakamori Y, Mio T, Mishima M.
    Successful treatment with pemetrexed in a patient with mucinous bronchioloalveolar carcinoma: long-term response duration with mild toxicity.
    J Thorac Oncol, 6:641-642, 2011.

  171. Masago K, Miura M, Toyama Y, Togashi Y, Mishima M.
    Good Clinical Response to Erlotinib in a Patient With Anaplastic Thyroid Carcinoma Harboring an Epidermal Growth Factor Somatic Mutation, L858R, in Exon 21.
    J Clin Oncol, 29:e465-467, 2011.

  172. Sakamori Y, Kim YH, Okuda C, Togashi Y, Kinose D, Masago K, Mio T, Uji A, Mishima M.
    Two Cases of Cancer-associated Retinopathy Combined with Small-cell Lung Cancer.
    Jpn J Clin Oncol, 41:669-673, 2011.

  173. Togashi Y, Kim YH, Masago K, Sakamori Y, Okuda C, Mio T, Mishima M.
    Long-term Survival in a Patient with Small-cell Lung Cancer Undergoing Hemodialysis Who Received Multiple Courses of Chemotherapy.
    Jpn J Clin Oncol, 41:582-585, 2011.

  174. Togashi Y, Kim YH, Masago K, Tamai K, Sakamori Y, Mio T, Mishima M.
    Pulmonary embolism due to internal jugular vein thrombosis in a patient with non-small cell lung cancer receiving bevacizumab.
    Int J Clin Oncol, 16:444-446, 2011.

  175. Wen X, Abe T, Kukihara H, Taguwa S, Mori Y, Tani H, Kato N, Suzuki T, Tatsumi M, Moriishi K, Matsuura Y.
    Elimination of hepatitis C virus from hepatocytes by a selective activation of therapeutic molecules.
    PLoS ONE, 6:e15967, 2011

  176. Ariumi Y, Kuroki M, Maki M, Ikeda M, Dansako H, Wakita T, Kato N.
    The ESCRT system is required for hepatitis C virus production.
    PLoS ONE, 6:e14517, 2011

  177. Mori K, Ikeda M, Ariumi Y, Dansako H, Wakita T, Kato N.
    Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system.
    Virus Res, 151(1):61-70, 2011

  178. Ikeda M, Kawai Y, Mori K, Yano M, Abe K, Nishimura G, Dansako H, Ariumi Y, Wakita T, Yamamoto K, Kato N.
    Anti-ulcer agent teprenone inhibits hepatitis C virus replication: Potential treatment for hepatitis C.
    Liver Int, 31(6):871-80, 2011

  179. Ariumi Y, Kuroki M, Kushima Y, Osugi K, Hijikata M, Maki M, Ikeda M, Kato N.
    Hepatitis C virus hijacks P-body and stress granule components around lipid droplets.
    J Virol, 85(14):6882-92, 2011

  180. Ueda Y, Mori K, Ariumi Y, Ikeda M, Kato N..
    Plural assay systems derived from different cell lines and hepatitis C virus strains are required for the objective evaluation of anti-hepatitis C virus reagents.
    Biochem Biophys Res Commun, 409(4):663-8, 2011

  181. Kumamoto H, Kobayashi M, Kato N, Balzarini J, Tanaka H.
    Synthesis of the 5’-fluoro-2’b-methyl analogues of neplanocin.
    Eur J Org Chem, 14:2685-91, 2011

  182. Fukuhara A, Masago K, Neo M, Fujibayashi S, Fujita S, Hatachi Y, Irisa K, Sakamori Y, Togashi Y, Kim YH, Mio T, Mishima M.
    Outcome of Surgical Treatment for Metastatic Vertebra Bone Tumor in Advanced Lung Cancer.
    Case Reports Oncol, 3:63-71, 2010.

  183. Masago K, Togashi Y, Fukudo M, Terada T, Irisa K, Sakamori Y, Fujita S, Kim YH, Mio T, Inui KI, Mishima M.
    Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation.
    Case Rep Oncol, 3:98-105, 2010.

  184. Togashi Y, Kim YH, Miyahara R, Irisa K, Sakamori Y, Masago K, Mio T, Date H, Mishima M.
    Octreotide, a somatostatin analogue, in the treatment of chylothorax associated with idiopathic fibrosing mediastinitis.
    Tohoku J Exp Med, 222:51-53, 2010.

  185. Togashi Y, Masago K, Mishima M, Fukudo M, Inui K.
    A case of radiation recall pneumonitis induced by erlotinib, which can be related to high plasma concentration.
    J Thorac Oncol, 5:924-925, 2010.

  186. Masago K, Fujita S, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, Nagai H, Irisa K, Sakamori Y, Okuda C, Mio T, Mishima M.
    Clinical Significance of Pretreatment C-Reactive Protein in Patients with Advanced Nonsquamous, Non-Small Cell Lung Cancer Who Received Gefitinib.
    Oncology, 79:355-362, 2010.

  187. Masago K, Fujita S, Kim YH, Hatachi Y, Fukuhara A, Irisa K, Nagai H, Sakamori Y, Togashi Y, Mio T, Mishima M.
    Phase I study of the combination of nedaplatin and gemcitabine in previously untreated advanced squamous cell lung cancer.
    Cancer Chemother Pharmacol, 67:325-330, 2011.

  188. Masago K, Fujita S, Mio T, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, Irisa K, Sakamori Y, Mishima M.
    Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancer.
    Med Oncol, 28:351-356, 2011.

  189. Masago K, Fukuhara A, Ito Y, Hatachi Y, Irisa K, Sakamori Y, Togashi Y, Fujita S, Kim YH, Mio T, Mishima M.
    Infectious background of febrile advanced lung cancer patients who received chemotherapy.
    Oncol Lett, 1:849-853, 2010.

  190. Togashi Y, Masago K, Fukudo M, Terada T, Fujita S, Irisa K, Sakamori Y, Kim YH, Mio T, Inui K, Mishima M.
    Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer.
    J Thorac Oncol, 5:950-955, 2010.

  191. Togashi Y, Masago K, Fukudo M, Terada T, Ikemi Y, Kim YH, Fujita S, Irisa K, Sakamori Y, Mio T, Inui K, Mishima M.
    Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis.
    J Thorac Oncol, 5:601-605, 2010.

  192. Mori K, Ikeda M, Ariumi Y, Kato N.
    Gene expression profile of Li23, a new human hepatoma cell line enables robust epatitis C virus replication: Comparison with HuH-7 and other hepatic cell lines.
    Hepatology Res, 40(12):1248–53, 2010

  193. Ikeda F, Dansako H, Nishimura G, Mori K, Kawai Y, Ariumi Y, Miyake Y, Takaki A, Nouso K,
    Iwasaki Y, Ikeda M, Kato N, Yamamoto K.
    Amino acid substitutions of hepatitis C virus core protein are not associated with intracellular antiviral
    response to interferon-a in vitro.
    Liver Int, 30(9):1324-31, 2010

  194. Nozaki A, Numata K, Morimoto M, Kondo M, Sugimori K, Morita S, Miyajima E, Ikeda M, Kato N, Maeda S, Tanaka K.
    Hydroxyurea suppresses hepatitis C virus replication in human: a phase i trial of oral hydroxyurea
    in chronic hepatitis C patients.
    Antiviral Therapy, 15(8):1179-83, 2010

  195. Yu S, Chen J, Wu M, Chen H, Kato N, Yuan Z.
    Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKε and DDX3.
    J General Virol, 91(8): 2080–90, 2010

  196. Tanaka T, Hasegawa Y, Saito M, Ikeda M, Kato N.
    Generation of single-chain Fvs against detergent-solubilized recombinant antigens with
    a simple coating procedure.
    J Biosci Bioeng, 110(3):374-6, 2010

  197. Shigoka M, Tsuchida A, Matsudo T, Nagakawa Y, Saito H, Suzuki Y, Aoki T, Murakami Y, Toyoda H, Kumada T, Bartenschlager R, Kato N, Ikeda M, Takashina T, Tanaka M, Suzuki R, Oikawa K, Takanashi M, Kuroda M.
    Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development.
    Path Int, 60(5):351-7, 2010

  198. Nozaki A, Morimoto M, Kondo M, Oshima T, Numata K, Fujisawa, Kaneko T, Miyajima E, Morita S, Mori K, Ikeda M, Kato N, Tanaka K.
    Hydroxyurea as an inhibitor of hepatitis C virus RNA replication.
    Arch Virol, 155(4):601-5, 2010

  199. Nakamura M, Saito H, Ikeda M, Hokari R, Kato N, Hibi T, Miura S.
    An antioxidant resveratrol significantly enhanced replication of hepatitis C virus.
    World J Gastroenterol, 16(2):184-92, 2010

  200. Oshiumi H, Ikeda M, Matsumoto M, Watanabe A, TakeuchI O, Akira S, Kato N, Shimotohno K, and Seya T.
    Hepatitis C virus core protein abrogates the DDX3 function that enhances IPS-1-mediated IFN-b induction.
    PLoS ONE, 5:e14258, 2010

  201. Marozin S, De Toni EN, Rizzani A, Altomonte J, Junger A, Schneider G, Thasler WE, Kato N, Schmid RM, Ebert O.
    Cell cycle progression or translation control is not essential for vesicular stomatitis virus oncolysis of hepatocellular carcinoma.
    PLoS ONE, 5(6):e10988, 2010